Welcome
Support Centre
25 July 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ ...Back to search results ] [ Print-friendly version ]
Research to improve economical anti-rabies treatment
ISRCTN ISRCTN30087513
DOI 10.1186/ISRCTN30087513
ClinicalTrials.gov identifier
EudraCT number
Public title Research to improve economical anti-rabies treatment
Scientific title A randomised comparative study of the immunogenicity of a modified intradermal post-exposure rabies vaccine regimen
Acronym N/A
Serial number at source 065947
Study hypothesis To find a single economical post-exposure rabies vaccine regimen suitable for use with all vaccines currently recommended by the World Health Organisation (WHO), by testing the initial immunogenicity of a new variation of current intradermal post-exposure treatment regimens. Any new method must induce a rapid initial immune response, in comparison with control regimens.
Lay summary Not provided at time of registration
Ethics approval After temporary recruitment problems, approval for the smaller study was received from the Oxfordshire Clinical Research Ethics Committee (ref: C01.078).
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Rabies vaccine
Participants - inclusion criteria 1. Healthy volunteers in Oxfordshire between the ages of 18 and 50 years, either sex
2. Have never had rabies vaccine before
3. Able to attend all appointments
Participants - exclusion criteria 1. Any previous rabies immunisation
2. Treatment with human immunoglobulins or blood transfusion within the past three months
3. The use of immunosuppressive drugs
4. Pregnancy
5. Uncertainty about returning for appointments during the year
6. Chloroquine cannot be taken for two weeks prior to vaccination at day zero until two weeks after vaccination at day 90
Anticipated start date 01/01/2005
Anticipated end date 30/07/2006
Status of trial Completed
Patient information material
Target number of participants 220
Interventions 220 healthy volunteers in the UK between the ages of 18 and 50 years will be recruited and randomised into one of four treatment groups of 55 people each. The standard intramuscular rabies post-exposure vaccine regimen will be compared with two current economical intradermal regimens and a new improved intradermal regimen.

Unfortunately, recruitment was badly affected by a general anti vaccination sentiment in UK resulting from the media campaign against MMR. Our intention to recruit from the armed forces was thwarted by bad experiences with multiple vaccinations, in particular against anthrax, in preparation for the Iraq war. The funds for the trial ran out last year and while seeking an extension of the grant, recruitment was stopped temporarily. We have re-evaluated what can be achieved using internal funds and honorary staff, and have now restarted recruiting. The strategy has been changed to carry out a smaller study. The size is reduced by elimination of three of the seven study arms. The remaining groups will still provide data on the most important objectives, and may give results which could alter routine rabies post-exposure treatment.
Primary outcome measure(s) Blood samples are taken to measure the level of rabies virus-neutralising antibody by the Rabies antibody responses (RIFFIT) method. The serological results of the test regimen will be compared with those of control reference regimens of proven clinical efficacy.
Secondary outcome measure(s) No secondary outcome measures
Sources of funding The Wellcome Trust (UK) (grant ref: 065947)
Trial website
Publications 2008 results in http://www.ncbi.nlm.nih.gov/pubmed/18431444
Contact name Prof  David  Warrell
  Address John Radcliffe Hospital
Nuffield Department of Clinical Medicine
Headington
  City/town Oxford
  Zip/Postcode OX3 9DU
  Country United Kingdom
  Tel +44 (0)1865 220968
  Fax +44 (0)1865 220984
  Email david.warrell@ndm.ox.ac.uk
Sponsor University of Oxford (UK)
  Address University Offices
Wellington Square
  City/town Oxford
  Zip/Postcode OX1 2JD
  Country United Kingdom
  Tel +44 (0)1865 270143
  Fax +44 (0)1865 280467
  Email research.services@admin.ox.ac.uk
  Sponsor website: http://www.ox.ac.uk
Date applied 22/07/2005
Last edited 12/12/2012
Date ISRCTN assigned 22/07/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.